MedTrace Logo

Optimizing Abiraterone Therapy

NCT02426333 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2019-09-13

No results posted yet for this study

Summary

The purpose of this study is to explore whether early abiraterone exposure is related to treatment response in patients with metastatic castration resistant prostate cancer. Furthermore to explore the relation between biomarkers and treatment response and drug exposure.

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

OTHER

Abiraterone Acetate

Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Nielka van Erp, PharmD, PhD · Radboud University Medical Center

  • Jack Schalken, PhD · Radboud University Medical Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2019-04-24
Completion
2019-08-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426333 on ClinicalTrials.gov